ArticleBMC pediatrics2026
SHAP based feature selection for machine learning prediction of mycoplasma pneumoniae pneumonia with atelectasis in children.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundMycoplasma pneumoniae pneumonia (MPP) with atelectasis in children is the most reported complication of MPP in children. It is associated with serious respiratory issues, pulmonary tissue damage and fibrosis, and systemic complications. Present diagnostic methods, which are mainly based on radiographic imaging, have drawbacks related to delayed case detection and radiation exposure. There is a need for a simple, non-invasive approach in the diagnosis. We aimed to develop machine learning (ML) models to identify MPP with atelectasis in children and support early risk stratification.
methodsWe conducted a retrospective study of 508 hospitalized pediatric patients with MPP from July 2022 to June 2024. Baseline clinical data were extracted from the electronic medical record system. Six tree-based ML models—decision tree (DT), random forest (RF), adaptive boosting (ADB), extreme gradient boosting (XGB), bayesian decision tree (BDT), and neural decision tree (NDT)—were developed. The SHapley Additive exPlanations (SHAP) was used to assess model feature importance, and final predictor subsets were determined through SHAP-guided forward feature selection. Models were tuned by Bayesian optimization within a nested five-fold cross-validation framework, and their performance was evaluated in an independent stratified validation cohort using receiver operating characteristic curve (AUROC), accuracy and decision curve analysis (DCA).
resultsSHAP-guided feature selection generated a specific feature set for each model. These features reflect systemic inflammatory burden, febrile status, adaptive immune response, and target-organ injury. In the training cohort, the RF model demonstrated the best performance, achieving an AUROC of 0.91 (95% CI 0.88–0.93). The performance of RF remained stable in the validation cohort, with an AUROC of 0.89 (95% CI 0.83–0.95). The model exhibited strong classification performance across other key metrics, including sensitivity, specificity, and negative predictive value. The results suggest that the model is generalizable with minimal overfitting.
conclusionThe interpretable RF model helps clinicians identify early cases of MPP that is complicated with atelectasis in children. This stable and interpretable method offers a practical tool for early risk stratification and timely decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.